The agreement values Boston-based Albireo at $952 million, with shareholders in the company also in line for another $10-per-share payout in a contingent value right (CVR) if Bylvay (odevixibat) gets approved for a follow-up indication.
Albireo secured approval in the US and Europe for the ileal bile acid transport inhibitor (IBATi) drug in 2021 for the treatment of pruritus (itching) in patients with rare disorder progressive familial intrahepatic cholestasis (PFIC), and has said sales should reach $24 million this year.
